Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Flupirtine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.92 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.92 |
| ▸ | KCNQ2 | O43526 | 9/20 | 0.92 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.92 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.92 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.92 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.92 |
| ▸ | ESR1 | P03372 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.92 |
| ▸ | CASP1 | P29466 | 1/20 | 0.92 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.92 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flupirtine SCHEMBL505375 | 0.98 | KCNQ2 (0.92) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL25009 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL3896230 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL29400613 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL15357226 | 0.96 | KCNQ2 (1.00) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL505456 | 0.95 | KCNQ2 (0.86) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL505958 | 0.95 | KCNQ2 (0.86) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL505535 | 0.95 | KCNQ2 (0.98) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL505847 | 0.95 | KCNQ2 (0.98) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 | |
| Flupirtine SCHEMBL28262990 | 0.95 | KCNQ2 (0.98) | KCNQ2KCNQ3PTGS2CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350009-B1 | SULFONATE SALTS OF FLUPIRTINE | TEVA GMBH (DE) | 2016-03-16 | — | — | EP | claimed |
| CN-103037848-A | An injectable dosage form of flupirtine | AWD PHARMA GMBH & CO KG | 2013-04-10 | — | — | CN | claimed |
| US-8222282-B2 | Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine | TEVA PHARMACEUTICALS USA, INC. (US) | 2012-07-17 | — | — | US | claimed |
| EP-2350009-A1 | SULFONATE SALTS OF FLUPIRTINE | AWD.pharma GmbH & Co.KG (DE) | 2011-08-03 | — | — | EP | claimed |
| US-20090318506-A1 | Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine | AWD. PHARMA GMBH & CO. KG (DE) | 2009-12-24 | — | — | US | claimed |
| WO-2009152142-A1 | SULFONATE SALTS OF FLUPIRTINE | AWD. PHARMA GMBH & CO. KG (DE) | 2009-12-17 | — | — | WO | claimed |
| US-20130096163-A1 | Injectable dosage form of flupirtine | AWD.PHARMA GMBH & CO. KG (DE) | 2013-04-18 | — | — | US | disclosed |
| EP-2579856-A1 | AN INJECTABLE DOSAGE FORM OF FLUPIRTINE | AWD.pharma GmbH & Co.KG (DE) | 2013-04-17 | — | — | EP | disclosed |
| CN-103037848-A | An injectable dosage form of flupirtine | AWD PHARMA GMBH & CO KG | 2013-04-10 | — | — | CN | disclosed |
| US-20120028930-A1 | FLUPIRTINE SALTS AND POLYMORPHS | BIONEVIA PHARMACEUTICALS INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011157719-A1 | AN INJECTABLE DOSAGE FORM OF FLUPIRTINE | AWD.PHARMA GMBH & CO. KG (DE) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318506-A1 | Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine | SSTR3, NPSR1, SSTR2 | HTR1A 85/4885ADRA2A 22/4885KCNQ2 721/4885 |
| US-20120028930-A1 | FLUPIRTINE SALTS AND POLYMORPHS | SULT2A1, TACR1, NPSR1 | HTR1A 154/4885ADRA2A 15/4885KCNQ2 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.